Sutureless amniotic membrane ProKera for ocular surface disorders: short-term results

Area of Science:

• Ophthalmology
• Regenerative Medicine
• Ocular Surface Disease

Background:

• Ocular surface disorders require effective management strategies.
• Sutureless amniotic membrane transplantation (AMT) offers a potential therapeutic option.

Purpose of the Study:

• To evaluate the indications and outcomes of sutureless amniotic membrane transplant (AMT), specifically ProKera, in managing various ocular surface disorders.
• To assess the efficacy and complications associated with ProKera implantation.

Main Methods:

• A retrospective chart review was conducted on 33 patients (35 eyes) who received ProKera implantation between June 2008 and May 2012.
• Data collected included patient demographics, indications for AMT, duration of device retention, ocular surface healing, follow-up duration, and complications.

Main Results:

• ProKera was used for nonhealing corneal ulcers (25.7%), neurotrophic keratopathy (31.4%), chemical injury (14.3%), and other conditions (28.6%).
• Success rates varied by indication: 44% for ulcers, 64% for neurotrophic keratopathy, 80% for chemical injury, and 70% for other indications.
• Discomfort occurred in 17.1% of cases, and primary condition recurrence was observed in 14.3%.

Conclusions:

• Sutureless amniotic membrane transplant (ProKera) is user-friendly and well-tolerated.
• ProKera demonstrates moderate success in treating corneal ulcers and encouraging results in acute chemical injuries.
• Recurrence of the primary condition is particularly associated with neurotrophic keratitis and dry eye syndrome.